Their major modes of action include presentation of B-cell receptor (BCR)-cognate antigens to CD4+ and potentially CD8+ T-cells [15–18], production of cytokines that can stimulate or suppress anti-tumor response [19–21], and production of tumor-specific antibodies [1–3] that may enhance killing of tumor cells via ADCC [8, 22], enhance antigen capture and presentation by dendritic cells [2], or form immune complexes that promote activation of MDSCs [23, 24]. The gene discussed is CD4; the disease is neoplasm.